These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10650144)

  • 1. Relative sparing of calretinin containing neurons in the substantia nigra of 6-OHDA treated rat parkinsonian model.
    Kim BG; Shin DH; Jeon GS; Seo JH; Kim YW; Jeon BS; Cho SS
    Brain Res; 2000 Feb; 855(1):162-5. PubMed ID: 10650144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calretinin and calbindin-D28k in dopaminergic neurons of the rat midbrain: a triple-labeling immunohistochemical study.
    Nemoto C; Hida T; Arai R
    Brain Res; 1999 Oct; 846(1):129-36. PubMed ID: 10536220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calretinin-containing axons and neurons are resistant to an intrastriatal 6-hydroxydopamine lesion.
    Tsuboi K; Kimber TA; Shults CW
    Brain Res; 2000 Jun; 866(1-2):55-64. PubMed ID: 10825480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of alkaline phosphatase in situ hybridization with immunohistochemistry: colocalization of calretinin-mRNA with calbindin and tyrosine hydroxylase immunoreactivity in rat substantia nigra neurons.
    Heppelmann B; Señaris R; Emson PC
    Brain Res; 1994 Jan; 635(1-2):293-9. PubMed ID: 7909717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys.
    Lavoie B; Parent A
    Neuroreport; 1991 Oct; 2(10):601-4. PubMed ID: 1684519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?
    Mouatt-Prigent A; Agid Y; Hirsch EC
    Brain Res; 1994 Dec; 668(1-2):62-70. PubMed ID: 7704619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDNF increases the density of cells containing calbindin but not of cells containing calretinin in cultured rat and human fetal nigral tissue.
    Meyer M; Zimmer J; Seiler RW; Widmer HR
    Cell Transplant; 1999; 8(1):25-36. PubMed ID: 10338273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calbindin-D 28kD immunofluorescence in ventral mesencephalic neurons labeled following injections of Fluoro-Gold in nucleus accumbens subterritories: inverse relationship relative to known neurotoxin vulnerabilities.
    Tan Y; Williams ES; Zahm DS
    Brain Res; 1999 Oct; 844(1-2):67-77. PubMed ID: 10536262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
    Andringa G; van Oosten RV; Unger W; Hafmans TG; Veening J; Stoof JC; Cools AR
    Eur J Neurosci; 2000 Aug; 12(8):3033-43. PubMed ID: 10971644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrastriatal implantation of interleukin-1. Reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain.
    Wang J; Bankiewicz KS; Plunkett RJ; Oldfield EH
    J Neurosurg; 1994 Mar; 80(3):484-90. PubMed ID: 7906726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axonal expression sites of tyrosine hydroxylase, calretinin- and calbindin-immunoreactivity in striato-pallidal and septal nuclei of the rat brain: a double-immunolabelling study.
    Seifert U; Härtig W; Grosche J; Brückner G; Riedel A; Brauer K
    Brain Res; 1998 Jun; 795(1-2):227-46. PubMed ID: 9622641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
    Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
    J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
    Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
    Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotrophin-4/5 selectively protects nigral calbindin-containing neurons in rats with medial forebrain bundle transections.
    Alexi T; Hefti F
    Neuroscience; 1996 Jun; 72(4):911-21. PubMed ID: 8735219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Protective effect of alkaloids from Piper longum in rat dopaminergic neuron injury of 6-OHDA-induced Parkinson's disease].
    Zheng L; Wang H; Ba YY; Liu HL; Wang M; Guo WW; Wu X; Yang H
    Zhongguo Zhong Yao Za Zhi; 2014 May; 39(9):1660-5. PubMed ID: 25095380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats.
    He Y; Lee T; Leong SK
    Neuroscience; 1999; 91(2):579-85. PubMed ID: 10366015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
    Bentlage C; Nikkhah G; Cunningham MG; Björklund A
    Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
    Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
    Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.